Galapagos NV (NASDAQ:GLPG - Free Report) - Analysts at Leerink Partnrs decreased their FY2024 earnings per share (EPS) estimates for Galapagos in a research note issued on Thursday, October 31st. Leerink Partnrs analyst F. Khurshid now forecasts that the biotechnology company will earn ($0.48) per share for the year, down from their prior estimate of $0.08. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Galapagos' current full-year earnings is $0.90 per share. Leerink Partnrs also issued estimates for Galapagos' Q4 2024 earnings at ($0.14) EPS, Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.83) EPS and FY2026 earnings at ($1.77) EPS.
A number of other equities research analysts have also weighed in on GLPG. Royal Bank of Canada dropped their price target on Galapagos from $32.00 to $30.00 and set a "sector perform" rating on the stock in a research note on Friday. Raymond James downgraded shares of Galapagos from an "outperform" rating to a "market perform" rating in a research report on Friday, August 2nd. Finally, Leerink Partners initiated coverage on shares of Galapagos in a report on Monday, September 9th. They issued a "market perform" rating and a $24.00 price target for the company. One investment analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $30.75.
Check Out Our Latest Research Report on Galapagos
Shares of NASDAQ:GLPG opened at $26.89 on Monday. The business's 50-day moving average is $29.24 and its 200 day moving average is $27.72. Galapagos has a 1 year low of $24.16 and a 1 year high of $42.46.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Headlands Technologies LLC boosted its holdings in Galapagos by 949.3% in the first quarter. Headlands Technologies LLC now owns 787 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 712 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Galapagos by 140.7% in the third quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company's stock worth $36,000 after buying an additional 736 shares during the last quarter. Signaturefd LLC grew its holdings in Galapagos by 48.1% during the second quarter. Signaturefd LLC now owns 3,872 shares of the biotechnology company's stock worth $96,000 after acquiring an additional 1,258 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Galapagos by 63.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company's stock worth $112,000 after acquiring an additional 1,510 shares during the period. Finally, Rhumbline Advisers raised its position in Galapagos by 21.6% during the second quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company's stock valued at $113,000 after acquiring an additional 814 shares in the last quarter. Institutional investors and hedge funds own 32.46% of the company's stock.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Galapagos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galapagos wasn't on the list.
While Galapagos currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.